AGEN

Allogenic iNKTs

COVID-19

Stage (next event)

Expected Date

Phase 1 Trial

TBD

Catalyst Info & Data Links

TITLE: Allogenic iNKTs as COVID-19 Phase 1 trial


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 1 Readout


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?  

  • TBD


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • Invariant natural killer T cells (iNKT cells) are a unique cell type that combines features of two critical arms of the immune system, T cells (adaptive immunity) and NK cells (innate immunity), making them invaluable in combating diseases like COVID-19 and cancer. Data from preclinical models that bear similarities to SARS-COV-2 suggest that iNKT cell therapy has the potential to eliminate the COVID-19 virus, dampen harmful inflammation, and promote protection from reinfection.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Tocagen's Promising Glioblastoma Therapy

AACR 2018 Amp Up

Investors Are Missing An Opportunity With Alkermes

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon